
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Table of Contents
over 23 years ago
Picking a Place to Growover 23 years ago
Pfizer Can Mold Its Future by Learning from the Pastover 23 years ago
Reputation: The Inside Storyover 23 years ago
Good Recruitment Practice = Patient Pullover 23 years ago
Networked Pharmaover 23 years ago
On Autopilot





